Blogs
Danaher Corporation (NYSE:DHR) and AstraZeneca PLC (NASDAQ:AZN) have announced a major partnership to accelerate the development and commercialization of advanced diagnostic tools aimed at expanding precision medicine. Leveraging DHR’s newly...
From the Aiosyn Blog IVDR represents a significant overhaul of regulations requiring more rigorous oversight, clinical validation assessed by a Notified Body, and stricter post-market surveillance (PMS). Aiosyn’s AI-powered...
New from the Proscia blog: Digital pathology has evolved far beyond improving quality and efficiency. It’s becoming a strategic gateway to business growth. This was the central message our CEO David West delivered during his breakout...
As life sciences R&D teams increasingly leverage digital pathology and AI to accelerate their precision medicine programs, Proscia’s Concentriq LS platform is handling unprecedented volumes of high-resolution images, complex annotations,...
New on the Proscia bMaximize your digital investment with pathologist-centered innovation Here at Proscia, we believe the key to achieving productivity and confidence in digital pathology lies in delivering an intelligent and intuitive...
Fortis: The institute will bring together a team of medical experts, including molecular hematology, oncology, neurology, paediatrics, pathology, and genomic scientists along with bioinformaticians and AI engineers Fortis Healthcare launched...
